Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22381450 | 0.80 | XDH (0.43) | XDHSLC22A12 | |
| SCHEMBL20179456 | 0.78 | XDH (0.55) | XDHSLC22A12 | |
| SCHEMBL22381453 | 0.77 | XDH (0.54) | XDHSLC22A12 | |
| SCHEMBL22381454 | 0.77 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL20929098 | 0.76 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL22364232 | 0.74 | XDH (0.68) | XDHSLC22A12 | |
| SCHEMBL22363577 | 0.70 | XDH (0.72) | XDHSLC22A12 | |
| SCHEMBL22353089 | 0.69 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL17941561 | 0.69 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL22276768 | 0.69 | SMN1; SMN2 (0.56) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.